TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26112283

Group type: EXPERIMENTAL
Intervention: Large positive or negative intrathoracic pressures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modest intrathoracic pressures or large lung volumes
Number of subjects: 0
Study: 24671538

Group type: EXPERIMENTAL
Intervention: d-cycloserine (DCS) 250 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 21515561

Group type: EXPERIMENTAL
Intervention: Eyelid closure (ELC) for 1 min
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Eyelid closure (ELC) for 3 min
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall group (ELC for 1 min and 3 min)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (no eyelid closure)
Number of subjects: 51
Study: 20402328

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 436
Study: 17160498

Group type: EXPERIMENTAL
Intervention: DFDBA/PRP combination
Number of subjects: 28

Group type: COMPARATOR
Intervention: PRP alone
Number of subjects: 28
Study: 15684017

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) combined with interstitial chemotherapy (carmustine) after microsurgery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 28
Study: 11991437

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day for 2 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 0
Study: 9489270

Group type: EXPERIMENTAL
Intervention: Empirically Supported Treatments (ESTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manualized treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scientist-practitioner model
Number of subjects: 0
Study: 7611583

Group type: EXPERIMENTAL
Intervention: 1 mg morphine intraarticularly diluted in 10 ml saline
Number of subjects: 59

Group type: COMPARATOR
Intervention: 1 mg morphine intravenously diluted in 10 ml saline (control)
Number of subjects: 59
Study: 2195225

Group type: EXPERIMENTAL
Intervention: Nylon monofilament 10-0 suture
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mersilene 10-0 suture
Number of subjects: 26
Study: 76170

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide in large doses
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 31
Study: 30845977

Group type: EXPERIMENTAL
Intervention: Permissive approach (antipyretic interventions only at ≥ 39.5 °C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Restrictive approach (antipyretic interventions at ≥ 37.5 °C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 27736795

Group type: COMPARATOR
Intervention: Standard regimen of split-dose 4L polyethylene-glycol (group A)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Split-dose sodium picosulphate/magnesium citrate (group B)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Individualized preparation based on a 3-item questionnaire (group C)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Split-dose 4L polyethylene-glycol
Number of subjects: 143
Study: 25647451

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23228248

Group type: EXPERIMENTAL
Intervention: Occlusal reduction (OR group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No occlusal reduction (NOR group)
Number of subjects: 54
Study: 22232849

Group type: EXPERIMENTAL
Intervention: 10 mg film-coated tablet (FCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg chewable tablet (CT)
Number of subjects: 0
Study: 19188334

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2‐1.4 microg/kg per hour)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Midazolam (0.02‐0.1 mg/kg per hour)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 375

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 375
Study: 16887430

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 15312472

Group type: EXPERIMENTAL
Intervention: Imipenem (IPM)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cefoperazone (CPZ)
Number of subjects: 13
Study: 10914936

Group type: EXPERIMENTAL
Intervention: p53 mutations (mutation+)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Age 60 years or older
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Unfavorable karyotypes
Number of subjects: 200

Group type: COMPARATOR
Intervention: p53 accumulation (mutation‐/accumulation+)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: p53 accumulation (mutation+)
Number of subjects: 200

Group type: COMPARATOR
Intervention: p53 accumulation
Number of subjects: 200
Study: 9314423

Group type: EXPERIMENTAL
Intervention: BNP infusion at a rate of 3.3 pmol x kg(‐1) x min(‐1) over 4 hours
Number of subjects: 8
Study: 8359274

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 13
Study: 3534509

Group type: EXPERIMENTAL
Intervention: Walking group
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Walking group (compliers)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 229
Study: 31791663

Group type: EXPERIMENTAL
Intervention: Low-dose combination intravitreal anti-PDGFRβ 1 mg and aflibercept 2 mg (LD combo)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: High-dose combination intravitreal anti-PDGFRβ 3 mg and aflibercept 2 mg (HD combo)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Intravitreal aflibercept injection (IAI) alone
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Intraocular inflammation incidence
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Anti-Platelet Trialists' Collaboration-defined arterial thromboembolic events incidence
Number of subjects: 505
Study: 29718421

Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg BID
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 26294293

Group type: COMPARATOR
Intervention: Calcium (1200 mg/day) and Vitamin D (800 IU/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg/day), Vitamin D (800 IU/day), and Strontium ranelate (2 g daily)
Number of subjects: 40
Study: 26200465

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.24 µg·kg·min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 10
Study: 24135387

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG) defined as 100-125 mg/dL
Number of subjects: 1690

Group type: EXPERIMENTAL
Intervention: Elevated HbA1c defined as 5.7-6.4%
Number of subjects: 1690

Group type: EXPERIMENTAL
Intervention: Both IFG and elevated HbA1c
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Addition of elevated HbA1c to the model with IFG
Number of subjects: 1690
Study: 21107327

Group type: EXPERIMENTAL
Intervention: losartan 50 mg per day, titrated to 100 mg per day for 13 months
Number of subjects: 288

Group type: COMPARATOR
Intervention: ramipril 5 mg per day, titrated to 10 mg per day for 13 months
Number of subjects: 288
Study: 19099689

Group type: EXPERIMENTAL
Intervention: Active Kawasaki disease (KD)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inactive Kawasaki disease (KD)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (non-infectious diseases)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (febrile patients)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Kawasaki disease patients with coronary artery lesions
Number of subjects: 56
Study: 16352807

Group type: EXPERIMENTAL
Intervention: Valganciclovir (V-GCV)
Number of subjects: 0
Study: 13677026

Group type: EXPERIMENTAL
Intervention: Fenspiride (Erespal) 80 mg per os 3 times a day for 10 days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard conservative treatment
Number of subjects: 82
Study: 10873730

Group type: EXPERIMENTAL
Intervention: Transperitoneal approach (n=7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Extraperitoneal approach (n=7)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 9118039

Group type: COMPARATOR
Intervention: Melphalan and Prednisone (MP)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone (VBMCP)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: VBMCP
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Crossover VBMCP for patients failing with MP
Number of subjects: 479

Group type: COMPARATOR
Intervention: MP
Number of subjects: 479
Study: 1492852

Group type: EXPERIMENTAL
Intervention: Loxiglumide 400 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Loxiglumide 800 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3786037

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30775944

Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diuretic therapy (DIUR-T)
Number of subjects: 0
Study: 25824810

Group type: EXPERIMENTAL
Intervention: TRUCLEAR System®
Number of subjects: 90

Group type: COMPARATOR
Intervention: Versapoint® system
Number of subjects: 90
Study: 23595617

Group type: EXPERIMENTAL
Intervention: Provox XtraHME
Number of subjects: 45

Group type: COMPARATOR
Intervention: Provox HME
Number of subjects: 45
Study: 21226577

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 19143907

Group type: EXPERIMENTAL
Intervention: Sildenafil (10(-6) M, 10(-5) M)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxazosin (10(-8) M, 3.10(-8) M, 10(-7) M)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of sildenafil and doxazosin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sildenafil (10(-6) M) with EFS
Number of subjects: 12
Study: 17314057

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) therapy, subcutaneous ingestion of 0.03-0.04 mg/kg once daily
Number of subjects: 24
Study: 15134414

Group type: EXPERIMENTAL
Intervention: Theraflex-TMJ cream
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 52
Study: 12651657

Group type: EXPERIMENTAL
Intervention: Remifentanil 100 microg IV
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Remifentanil (25 and 50 microg IV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Remifentanil groups (25, 50, and 100 microg IV)
Number of subjects: 20
Study: 9613278

Group type: EXPERIMENTAL
Intervention: Ketamine 10 mg (1 ml)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.9% saline (1 ml)
Number of subjects: 100
Study: 7851372

Group type: EXPERIMENTAL
Intervention: Intense exercise at 5.6 m.s‐1 (0% incline)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intense exercise at +4% incline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intense exercise at +7% incline
Number of subjects: 9
Study: 3200265

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (1200 mg per day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Aspirin (1300 mg per day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 68
Study: 4700326

Group type: EXPERIMENTAL
Intervention: Gastrojejunostomy
Number of subjects: 547

Group type: COMPARATOR
Intervention: Pyloroplasty
Number of subjects: 547
Study: 30738713

Group type: EXPERIMENTAL
Intervention: Percutaneous approach (PA) for management of biliary stones
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (patients with biliary stenosis)
Number of subjects: 91
Study: 26883793

Group type: EXPERIMENTAL
Intervention: Healthy, Safe, and Tobacco‐free Worksites programme
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed‐intervention control
Number of subjects: 20
Study: 26084670

Group type: EXPERIMENTAL
Intervention: Online self-help intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Active comparison group exercise
Number of subjects: 80
Study: 23472197

Group type: EXPERIMENTAL
Intervention: CDP323 100 mg bid
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: CDP323 500 mg bid
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: CDP323 1000 mg qd
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: CDP323 1000 mg bid
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 21153659

Group type: EXPERIMENTAL
Intervention: Refined 2‐regression model
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Klippel and Heil equations
Number of subjects: 48

Group type: COMPARATOR
Intervention: 2008 Crouter 2‐regression model
Number of subjects: 48
Study: 19695452

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators (ICDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical judgment in circumstances with limited data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research initiatives
Number of subjects: 0
Study: 17100682

Group type: EXPERIMENTAL
Intervention: RAPIDO Guiding Catheter System (Group R)
Number of subjects: 74

Group type: COMPARATOR
Intervention: RAPIDO ADVANCE Guiding Catheter System (Group A)
Number of subjects: 74
Study: 14656749

Group type: EXPERIMENTAL
Intervention: Lipid administration in ARDS patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo administration in ARDS patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lipid administration in patients without ARDS
Number of subjects: 19
Study: 11434404

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 58

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Citalopram and Paroxetine
Number of subjects: 58
Study: 9402077

Group type: EXPERIMENTAL
Intervention: Seropositivity to H. ducreyi
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Seropositivity to HSV-2
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Seropositivity to syphilis
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Seroconversion to H. ducreyi and HSV-2
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Seroconversion to HSV-2 and H. ducreyi during HIV seroconversion interval
Number of subjects: 225
Study: 8357283

Group type: EXPERIMENTAL
Intervention: Histrionic portrayal
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Businesslike portrayal
Number of subjects: 44

Group type: COMPARATOR
Intervention: Verbatim transcript
Number of subjects: 44
Study: 3206197

Group type: EXPERIMENTAL
Intervention: Special caries preventive measures for 1 year
Number of subjects: 124

Group type: COMPARATOR
Intervention: Routine prevention procedures
Number of subjects: 124
Study: 31767947

Group type: EXPERIMENTAL
Intervention: Lidocaine lubricant (Xylocaine 2%)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard lubricant (placebo)
Number of subjects: 13
Study: 29532453

Group type: EXPERIMENTAL
Intervention: Higher fasting glucose
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin A1c (A1c)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Higher subscapular skinfolds
Number of subjects: 82
Study: 28501287

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 266

Group type: COMPARATOR
Intervention: Conventional pain management
Number of subjects: 266
Study: 25897797

Group type: EXPERIMENTAL
Intervention: Prodromal Detection and Treatment program (including information campaigns and detection teams)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group from Bergen and Østfold)
Number of subjects: 0
Study: 23103936

Group type: EXPERIMENTAL
Intervention: Progressive resistance training for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Progressive muscle relaxation training for 12 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 100
Study: 20889164

Group type: EXPERIMENTAL
Intervention: Succimer chelation treatment
Number of subjects: 767

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 767
Study: 18336963

Group type: EXPERIMENTAL
Intervention: Twinrix vaccine administered according to a 0-, 1-, and 6-month schedule.
Number of subjects: 59
Study: 16464519

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg for 10 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15690118

Group type: EXPERIMENTAL
Intervention: Enhanced Sexual Health Intervention (ESHI)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 147
Study: 11737908

Group type: EXPERIMENTAL
Intervention: Short-term infusion of corticosteroids
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20000
Study: 9240487

Group type: EXPERIMENTAL
Intervention: Cognitive Difficulties Scale (CDS)
Number of subjects: 63
Study: 8477564

Group type: EXPERIMENTAL
Intervention: MS Contin tablets 90 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Oramorph SR tablets 30 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Oramorph SR tablets 90 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: MS Contin tablets 30 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: MS Contin tablets
Number of subjects: 151

Group type: COMPARATOR
Intervention: Oramorph SR tablets
Number of subjects: 151
Study: 2962005

Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 31952145

Group type: EXPERIMENTAL
Intervention: Gardening activity program (low to moderate intensity physical activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gardening activity program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-gardening) group
Number of subjects: 0
Study: 31138315

Group type: EXPERIMENTAL
Intervention: magnesium citrate
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: magnesium oxide
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: magnesium sulfate
Number of subjects: 162

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 162
Study: 27889103

Group type: EXPERIMENTAL
Intervention: Sympathectomy (excision of T3 ganglia)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sympathicotomy (interruption of sympathetic chain at T2 to T3 level with ganglion sparing)
Number of subjects: 60
Study: 25306888

Group type: EXPERIMENTAL
Intervention: Nasal budesonide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nasal placebo
Number of subjects: 24
Study: 24124328

Group type: EXPERIMENTAL
Intervention: AN-PEP
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21504886

Group type: EXPERIMENTAL
Intervention: Tobacco dependence treatment RCT incorporating behavioral counseling and nicotine replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Women who agreed to enroll in the RCT
Number of subjects: 0
Study: 19567215

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study: 17698902

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 4 IU subcutaneously every other day for 3 months
Number of subjects: 22
Study: 15507059

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/d
Number of subjects: 1392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1392
Study: 12536693

Group type: EXPERIMENTAL
Intervention: Buflomedil 100 mg.d‐1
Number of subjects: 58
Study: 9270084

Group type: EXPERIMENTAL
Intervention: Systemic alpha1-receptor blockade (BLK)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -40 mm Hg during BLK
Number of subjects: 13

Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP) during PLA
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: BLK
Number of subjects: 13
Study: 7892725

Group type: EXPERIMENTAL
Intervention: Extracorporeal impulse lithotripsy (EIL) combined with supravesical endourological techniques
Number of subjects: 1311

Group type: EXPERIMENTAL
Intervention: X-ray endoscopy
Number of subjects: 1311
Study: 3301710

Group type: EXPERIMENTAL
Intervention: 600 mg femoxetine daily for 16 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo daily for 16 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Femoxetine in subgroups of patients with obesity problems for more than 20 years
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Femoxetine in subgroups of patients previously in anorectic treatment
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Femoxetine
Number of subjects: 73
Study: 31617649

Group type: EXPERIMENTAL
Intervention: Crocin (two capsules per day for 28 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (two capsules per day for 28 days)
Number of subjects: 40
Study: 28554732

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 32
Study: 25629740

Group type: EXPERIMENTAL
Intervention: 30 mg of subcutaneous icatibant
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard therapy (intravenous prednisolone 500 mg plus clemastine 2 mg)
Number of subjects: 27
Study: 23339387

Group type: EXPERIMENTAL
Intervention: Granulocyte and monocyte/macrophage adsorptive apheresis (GMA)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Leukocytapheresis (LCAP)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both GMA and LCAP
Number of subjects: 98

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 98